Skip to main content
    A

    Arcturus Therapeutics Holdings Inc (ARCT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.31
    -0.05 (-0.60%)

    Market Cap: $240.96M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Arcturus Therapeutics Holdings Inc (ARCT) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Arcturus Therapeutics Holdings (ARCT) trades at 7.7x sales and 1.4x book value. Its P/S of 7.7x is above its 5-year median of 3.8x. Its forward P/E is 2.5x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E2.5x
    Price to sales7.7x
    Price to book1.4x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 83.3% above 4.2x and its P/B is 46.2% below 2.6x.

    MultipleCurrent5-year median10-year median
    P/S7.7x3.8x4.2x
    P/B1.4x2.2x2.6x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 110 to 120 months (10-year).

    Valuation History

    Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 1.9x in 2017 to 88.0x in 2020.

    Year endPriceP/EP/SP/B
    2025$6.13N/A2.0x0.8x
    2024$16.97N/A3.0x1.9x
    2023$31.53N/A5.0x3.0x
    2022$16.9649.9x2.2x1.7x
    2021$37.01N/A78.8x4.3x
    2020$43.38N/A88.0x2.9x
    2019$10.87N/A5.8x6.1x
    2018$4.53N/A2.9x3.4x
    2017$7.95N/A1.9x2.4x
    2016$14.70N/AN/A1.2x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ARCT

    What is ARCT's forward P/E ratio?

    Arcturus Therapeutics Holdings has a forward P/E ratio of 2.5x.

    Is ARCT stock overvalued?

    GNG's valuation label for ARCT is Undervalued.

    What is ARCT's price to sales ratio?

    Arcturus Therapeutics Holdings has a price to sales ratio of 7.7x.